Stable expression of Leptospira interrogans antigens in auxotrophic Mycobacterium bovis BCG

Seixas, Fabiana Kömmling; Borsuk, Sibele; Fagundes, Michel Quevedo; Hartwig, Daiane Drawanz; Silva, Éverton F. da; Cerqueira, Gustavo M.; Dellagostin, Odir Antônio

doi:10.4067/s0716-97602010000100003

Cited by 8 publications

(5 citation statements)

References 22 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1). The most used auxotrophic targets for TB vaccination are the amino acids lysine (Nascimento et al 2009;Pavelka et al 2003), leucine (Borsuk et al 2007;Chambers et al 2000;Rizzi et al 2012;Seixas et al 2010), and methionine (McAdam et al 1995;Sampson et al 2011;Smith et al 2001), and the vitamin pantothenate (Chege et al 2013;Sambandamurthy et al 2002;Sampson et al 2011). Although widely used for studies in new TB vaccination strategies, auxotrophic approach has been used just once as an immunotherapy strategy for bladder cancer in an in vitro study (Begnini et al 2013).…”

Section: Modifying Bcg Strainsmentioning

confidence: 99%

Recombinant Mycobacterium bovis BCG for immunotherapy in nonmuscle invasive bladder cancer

Begnini

Buss

Collares

et al. 2015

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

In the past three decades, intravesical instillation of Mycobacterium bovis bacille Calmette-Guérin (BCG) has been used for treating bladder cancer and it still remains at the forefront of immunotherapy for cancer patients. Although BCG-based therapy is the most effective intravesical therapy for this kind of tumor and represents the only agent known to reduce progression into muscle invasive bladder cancer, BCG is ineffective in approximately 30-40 % of cases and disease recurs in up to 50 % of patients. Since that BCG is considered an effective vehicle for delivery of antigens due to its unique characteristics, the genetic manipulation of these mycobacteria has been appealing in the search for less toxic and more potent therapeutic agents for bladder cancer immunotherapy. Herein, we discuss current advances in recombinant BCG construction, research, concerns, and future directions to promote the development of this promising immunotherapeutic approach for bladder cancer.

show abstract

Section: Modifying Bcg Strainsmentioning

confidence: 99%

Recombinant Mycobacterium bovis BCG for immunotherapy in nonmuscle invasive bladder cancer

Begnini

Buss

Collares

et al. 2015

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

show abstract

“…The system described by Borsuk et al (2007) was further used for the expression of antigens from Leptospira interrogans [ 24 ] and M. bovis [ 25 ]. Seixas et al (2010) constructed two recombinant BCG Δ leuD strains, each expressing different leptospiral antigens.…”

Section: Targets For Construction and Applications Of Auxotrophic Bcg...mentioning

confidence: 99%

“…Seixas et al (2010) constructed two recombinant BCG Δ leuD strains, each expressing different leptospiral antigens. Both strains were 100% stable in mice after 18 weeks of the experiment, whereas the BCG Pasteur strains harboring the same plasmids showed only a 7% stability in vivo in the same period post-inoculation [ 24 ]. A recombinant BCG strain overexpressing Ag85B was also developed using the Δ leuD auxotrophic system and was evaluated as a vaccine against bovine tuberculosis.…”

Section: Targets For Construction and Applications Of Auxotrophic Bcg...mentioning

confidence: 99%

Auxotrophic Mycobacterium bovis BCG: Updates and Perspectives

et al. 2022

Self Cite

View full text Add to dashboard Cite

Mycobacterium bovis BCG has been used for a century as the only licensed vaccine against tuberculosis. Owing to its strong adjuvant properties, BCG has also been employed as an oncological immunotherapeutic as well as a live vaccine vector against other pathogens. However, BCG vaccination has limited efficacy in protecting against adult forms of tuberculosis (TB), raises concerns about its safety in immunocompromised populations, compromises the diagnosis of TB through the tuberculin test and lacks predictability for successful antigen expression and immune responses to heterologous antigens. Together, these factors propelled the construction and evaluation of auxotrophic BCG strains. Auxotrophs of BCG have been developed from mutations in the genes required for their growth using different approaches and have shown the potential to provide a model to study M. tuberculosis, a more stable, safe, and effective alternative to BCG and a vector for the development of recombinant live vaccines, especially against HIV infection. In this review, we provide an overview of the strategies for developing and using the auxotrophic BCG strains in different scenarios.

show abstract

“…In addition, this method also allows for the development of auxotrophic strains, including strain, where genes involved in the synthesis of metabolites are deleted, strains without antibiotic resistance markers, and strains displaying stable expression both in vitro or in vivo (Borsuk et al 2007;Seixas et al 2010;Rizzi et al 2017).…”

Section: Bcg In Melanoma Immunotherapymentioning

confidence: 99%

Mycobacterium bovis BCG in metastatic melanoma therapy

Benitez

Bender

Oliveira

et al. 2019

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

Melanoma is the most aggressive form of skin cancer, with a high mortality rate and with 96,480 new cases expected in 2019 in the USS. BRAF V600E , the most common driver mutation, is found in around 50% of melanomas, contributing to tumor growth, angiogenesis, and metastatic progression. Dacarbazine (DTIC), an alkylate agent, was the first chemotherapeutic agent approved by the US Food and Drug Administration (FDA) used as a standard treatment. Since then, immunotherapies have been approved for metastatic melanoma (MM) including ipilimumab and pembrolizumab checkpoint inhibitors that help decrease the risk of progression. Moreover, Mycobacterium bovis Bacillus Calmette-Guerin (BCG) serves as an adjuvant therapy that induces the recruitment of natural killer NK, CD4 + , and CD8 + T cells and contributes to antitumor immunity. BCG can be administered in combination with chemotherapeutic and immunotherapeutic agents and can be genetically manipulated to produce recombinant BCG (rBCG) strains that express heterologous proteins or overexpress immunogenic proteins, increasing the immune response and improving patient survival. In this review, we highlight several studies utilizing rBCG immunotherapy for MM in combination with other therapeutic agents.

show abstract

Stable expression of Leptospira interrogans antigens in auxotrophic Mycobacterium bovis BCG

Cited by 8 publications

References 22 publications

Recombinant Mycobacterium bovis BCG for immunotherapy in nonmuscle invasive bladder cancer

Recombinant Mycobacterium bovis BCG for immunotherapy in nonmuscle invasive bladder cancer

Auxotrophic Mycobacterium bovis BCG: Updates and Perspectives

Mycobacterium bovis BCG in metastatic melanoma therapy

Contact Info

Product

Resources

About